Publications (9)50.03 Total impact
-
Article: Subacute stent thrombosis successfully treated with thrombolysis and glycoprotein IIb/IIIa inhibition.
Heart (British Cardiac Society) 05/2005; 91(4):488. · 4.22 Impact Factor -
Article: Resolution of intracoronary thrombus with direct thrombin inhibition in a cocaine abuser.
Heart (British Cardiac Society) 06/2004; 90(5):501. · 4.22 Impact Factor -
Article: Intermittent opening of a mitral valve tilting disc prosthesis 23 years after implantation caused by circumferential pannus.
Heart (British Cardiac Society) 10/2003; 89(9):1049. · 4.22 Impact Factor -
Article: Successful use of the Guardwire Plus distal embolisation protection device in a native left anterior descending coronary artery.
Heart (British Cardiac Society) 01/2003; 88(6):648. · 4.22 Impact Factor -
Article: Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide.
[show abstract] [hide abstract]
ABSTRACT: Flow-mediated dilatation (FMD) of the brachial artery assessed by high-resolution ultrasound is widely used to measure endothelial function. However, the technique is not standardized, with different groups using occlusion of either the wrist or the upper arm to induce increased blood flow. The validity of the test as a marker of endothelial function rests on the assumption that the dilatation observed is endothelium-dependent and mediated by nitric oxide (NO). We sought to compare the NO component of brachial artery dilatation observed following wrist or upper arm occlusion. Dilatation was assessed before and during intra-arterial infusion of the NO synthase inhibitor N(G)-monomethyl-L-arginine (L-NMMA) following occlusion of (i) the wrist (distal to ultrasound probe) and (ii) the upper arm (proximal to ultrasound probe) for 5 min in ten healthy males. Dilatation was significantly greater after upper arm occlusion (upper arm, 11.62+/-3.17%; wrist, 7.25+/-2.49%; P=0.003). During L-NMMA infusion, dilatation after wrist occlusion was abolished (from 7.25+/-2.49% to 0.16+/-2.24%; P<0.001), whereas dilatation after upper arm occlusion was only partially attenuated (from 11.62+/-3.17% to 7.51+/-2.34%; P=0.006). The peak flow stimulus was similar after wrist and upper arm occlusion. We conclude that dilatation following upper arm occlusion is greater than that observed after wrist occlusion, despite a similar peak flow stimulus. L-NMMA infusion revealed that FMD following wrist occlusion is mediated exclusively by NO, while dilatation following upper arm occlusion comprises a substantial component not mediated by NO, most probably related to tissue ischaemia around the brachial artery. FMD following wrist occlusion may be a more valid marker of endothelial function than dilatation following upper arm occlusion.Clinical Science 01/2002; 101(6):629-35. · 4.61 Impact Factor -
Article: Folate, homocysteine, endothelial function and cardiovascular disease. What is the link?
[show abstract] [hide abstract]
ABSTRACT: Elevated plasma homocysteine concentrations are associated with an increased risk of cardiovascular disease, but the relationship has not been proven to be causal. Folate is the strongest nutritional and pharmacological determinant of plasma homocysteine concentrations, which also interact with the genetic variation in methylenetetrahydrofolate reductase (MTHFR). Endothelial dysfunction due to reduced nitric oxide bioavailability is an early feature of vascular pathology. This can be assessed noninvasively by measurement of flow-mediated dilatation. Human studies on folic acid, homocysteine and endothelial function are reported. It is proposed that folic acid in high doses may have beneficial effects on endothelial function, which are independent of homocysteine lowering.Biomedecine [?] Pharmacotherapy 11/2001; 55(8):425-33. · 2.00 Impact Factor -
Article: Improving endothelial vasomotor function.
BMJ 09/2001; 323(7309):352-3. · 14.09 Impact Factor -
Article: Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide?
[show abstract] [hide abstract]
ABSTRACT: Homocysteine is a risk factor for coronary artery disease (CAD). Folic acid lowers homocysteine and may improve endothelial function in CAD, although the mechanism is unclear. We investigated the effect of folic acid on endothelial function, homocysteine, and oxidative stress in patients with CAD. We also examined the acute effect of 5-methyltetrahydrofolate (5-MTHF), the principal circulating folate, on endothelial function in vivo and on intracellular superoxide in cultured endothelial cells. A randomized crossover study of folic acid (5 mg daily) for 6 weeks was undertaken in 52 patients with CAD. Ten further patients were given intra-arterial 5-MTHF. Endothelial function was assessed by flow-mediated dilatation (FMD). Folic acid increased plasma folate (P<0.001), lowered homocysteine by 19% (P<0.001), and improved FMD (P<0.001). FMD improvement did not correlate with homocysteine reduction. Malondialdehyde and total plasma antioxidant capacity, markers of oxidative stress, were unchanged. 5-MTHF acutely improved FMD (P<0.001) without altering homocysteine (P=0.47). In vitro, 5-MTHF abolished homocysteine-induced intracellular superoxide increase (P<0.001); this effect was also observed with folic acid and tetrahydrobiopterin. Our data support the beneficial effect of folic acid on endothelial function in CAD but suggest that the mechanism is independent of homocysteine. Reduction of intracellular endothelial superoxide may have contributed to the effect.Arteriosclerosis Thrombosis and Vascular Biology 08/2001; 21(7):1196-202. · 6.37 Impact Factor -
Article: Homocysteine and endothelial function.
Cardiovascular Research 07/1999; 42(3):578-82. · 6.06 Impact Factor
Top co-authors
Top Journals
Institutions
-
2001–2002
-
Heart Research Institute
Norwich, ENG, United Kingdom
-
